Mesoblast Limited
General ticker "MEOBF" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.7B (TTM average)
Mesoblast Limited follows the US Stock Market performance with the rate: 25.7%.
Estimated limits based on current volatility of 0.2%: low 1.70$, high 1.71$
Factors to consider:
- Total employees count: 108 as of 2016
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-06-30 to 2027-06-30
- 2025-06-30 to 2026-06-30 estimated range: [0.65$, 1.78$]
- 2026-06-30 to 2027-06-30 estimated range: [0.61$, 1.66$]
Short-term MEOBF quotes
Long-term MEOBF plot with estimates
Financial data
| YTD | 2023-06-30 | 2024-06-30 | 2025-06-30 |
|---|---|---|---|
| Operating Revenue | $7.50MM | $5.90MM | $17.20MM |
| Operating Expenses | $76.79MM | $90.05MM | $79.64MM |
| Operating Income | $-69.29MM | $-84.15MM | $-62.44MM |
| Non-Operating Income | $-12.81MM | $-4.00MM | $-39.37MM |
| Interest Expense | $19.44MM | $20.66MM | $23.32MM |
| R&D Expense | $27.19MM | $25.35MM | $34.81MM |
| Income(Loss) | $-82.10MM | $-88.15MM | $-101.81MM |
| Taxes | $-0.21MM | $-0.19MM | $0.33MM |
| Profit(Loss)* | $-81.89MM | $-87.96MM | $-102.14MM |
| Stockholders Equity | $501.84MM | $480.36MM | $597.44MM |
| Inventory | $0.00MM | $0.00MM | $22.25MM |
| Assets | $669.41MM | $669.15MM | $784.68MM |
| Operating Cash Flow | $-63.27MM | $-48.46MM | $-49.95MM |
| Capital expenditure | $0.31MM | $0.33MM | $0.73MM |
| Investing Cash Flow | $-0.19MM | $-0.10MM | $0.12MM |
| Financing Cash Flow | $74.50MM | $40.25MM | $147.34MM |
| Earnings Per Share** | $-0.10 | $-0.09 | $-0.08 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.